NOXOPHARM-LIMITED
25.8.2021 14:37:12 CEST | Business Wire | Press release
Australian clinical-stage drug development company Noxopharm (ASX:NOX) has released preliminary top-line data from its NOXCOVID Phase I clinical trial testing the suitability of idronoxil (Veyonda® ), a TBK1 (TANK-binding kinase 1) inhibitor, as an anti-inflammatory in patients with moderate COVID-19 disease. Based on initial positive results, Noxopharm has started discussions to add Veyonda to one of the global clinical trial programs looking at identifying effective anti-inflammatory therapies in COVID-19 disease.
The relevance of blocking TBK1 is seen as important in two respects: (i) ability to block a dysfunctional immune response to RNA viruses such as coronavirus and influenza virus; (ii) potential to avoid the adverse immune-suppressing effects of standard anti-inflammatory drugs such as prednisone and dexamethasone in potentially slowing viral clearance and increasing the risk of secondary infections.
“The NOXCOVID Phase I clinical trial is highly encouraging for Veyonda in this role as a high proportion of the patients were experiencing elevated inflammation,” said Noxopharm CEO and Managing Director Graham Kelly . “In this trial, no major safety issues were identified and 37 of 38 patients hospitalized with moderate respiratory disease recovered.”
“Based on what is known today, Veyonda’s properties give it the potential to address a gap in our armory of COVID-19 therapeutics,” said Marcel Nold , M.D., professor of pediatric immunology at Monash University and the Hudson Institute and pediatrician at Monash Children’s Hospital. “Patients can self-administer, allowing its use in their own home. Its mechanism of action may enable treatment of moderately ill COVID-19 patients and, importantly, it could also be effective against many other viruses. In Veyonda, Noxopharm has an exciting opportunity at hand.”
About Noxopharm
Noxopharm Limited (ASX:NOX) is an Australian clinical-stage drug development company focused on the treatment of cancer and cytokine storm (septic shock).
Veyonda® is the Company’s first pipe-line drug candidate currently in Phase 2 clinical trialling. Veyonda® has two main drug actions – a moderating effect on the ceramide/sphingosine-1-phosphate balance and inhibition of STING signalling. Activity against the former target contributes to its dual-acting oncotoxic and immunomodulatory functions designed to enhance the effectiveness and safety of standard oncology treatments, i.e., chemotherapies, radiation therapies and immune checkpoint inhibitors. Activity against the latter target provides an anti-inflammatory effect, as well as contributing to an anti-cancer action, but also potentially blocking septic shock.
Noxopharm is running comprehensive drug discovery programs in both oncology and inflammation, and is the major shareholder of US biotechnology company, Nyrada Inc (ASX:NYR), which is active in the areas of drug development for cardiovascular and neurological diseases.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210825005462/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Adtran sets intra-data center benchmark with all-new ultra-low-power LiteWave800™ LPO module10.3.2026 14:00:00 CET | Press release
News summary: AI clusters and GPU fabrics demand massive capacity, yet traditional 800G optics increase energy consumption, heat and cost burdens Adtran’s LiteWave800™ introduces a new class of ultra-low-power, low-latency DR8 LPO modules built on a fully re-engineered design Breakthrough energy efficiency of 1pJ/bit enables greener, scalable intra-data center links for next-generation AI and cloud workloads Adtran today launched LiteWave800™, an ultra‑low‑power 800Gbit/s DR8 linear pluggable optics (LPO) module engineered to help data centers address the power, latency, thermal and bandwidth demands of modern AI and machine-learning (ML) workloads. As GPU clusters grow and short-reach links scale across dense server racks, operators need 800Gbit/s optics that deliver higher capacity within strict power and cooling limits. LiteWave800™ answers this challenge with a fully re-engineered architecture that significantly reduces energy consumption. Operating at just 1pJ/bit and consuming on
Hyperice Introduces Hypervolt 3 Line: More Powerful, Quieter, and Longer-Lasting Percussion Massage Devices10.3.2026 14:00:00 CET | Press release
Upgraded Line Includes Redesigned Head Attachments and New Carry Case for an Enhanced Warm-Up and Recovery Experience Hyperice, a high-performance wellness brand, today announced the global launch of the Hypervolt 3 line, its most advanced percussion massage technology to date. The three-device line features the Hypervolt Go 3 ($149), the Hypervolt 3 ($249), and the Hypervolt 3 Pro ($349) — achieving significant performance upgrades across the board at more accessible price points than industry competitors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260310934508/en/ The Hypervolt 3 line enables users to massage away stress and tension, loosen muscle knots, maintain flexibility and range of motion, accelerate warm-up before workouts, and recover quickly after activity. Hyperice has built its reputation over the last 15 years on one guiding principle: elite-level recovery technology designed to help everyone perform and mo
Verifone and Thales Unlock Seamless Global Connectivity for Payment Terminals10.3.2026 14:00:00 CET | Press release
Thales today announced a partnership with Verifone, a global leader in payment terminal solutions, to connect Verifone’s next-generation point-of-sale (POS) terminals using Thales eSIM technology. The collaboration aims to simplify device deployment and enable secure, flexible connectivity for payment terminals worldwide; as connectivity can be provisioned, managed and updated remotely throughout the device lifecycle. By using Thales eSIM management platform, Verifone removes the need for removable SIM cards and country-specific hardware versions, significantly reducing operational complexity for manufacturers and service providers alike. At the core of this partnership is Thales’s leadership in eSIM management for large-scale connected devices, enabling remote connectivity provisioning and management, in line with the latest GSMA SGP.32 IoT specifications. These standards support secure and interoperable management of connectivity profiles, making it possible to deploy devices globall
Nexthop AI Unveils Transformative, industry-leading Scale-out and Scale-across Switches engineered for Hyperscalers & NeoClouds10.3.2026 13:45:00 CET | Press release
Underlines focus on power efficient solutions, deployment velocity and open networking Nexthop AI, the leading pioneer of highly efficient AI Networking, today launched a range of products for scale-out, scale-across and front-end applications for cloud and AI datacenters. The launch portfolio sets new standards for performance, power efficiency, and deployment speed - very critical metrics in AI infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260310990709/en/ Nexthop AI's highly efficient scale-out and scale-across AI networking portfolio Nexthop also unveiled the Disaggregated Spine architecture - a new, highly efficient, scale-across network design developed in collaboration with a large hyperscaler. This innovative architecture decomposes the traditional monolithic chassis running proprietary software into independent, optimized, functional tiers. It features a scale-across leaf tier (data center fabric fa
Nexthop AI Accelerates Into Hypergrowth With Oversubscribed $500M Series B Funding, Catapulting the Company’s Valuation to $4.2 Billion10.3.2026 13:45:00 CET | Press release
New Tier-1 Investors, Led by Lightspeed Venture Partners, Join to Fuel Development of Highly Efficient, Next-Generation AI and Cloud Networking Solutions Nexthop AI, the leading pioneer of highly efficient AI Networking, today announced successful closure of an oversubscribed $500 Million Series B funding round, catapulting the company’s valuation to $4.2 Billion. This round was spearheaded by Lightspeed Venture Partners, with Andreessen Horowitz joining as a major investor, and participation from Altimeter and all existing investors. “The rapid growth of AI is forcing a fundamental rethink of data center network architecture — and that creates one of the largest infrastructure market opportunities we’ve seen in a generation, with the potential to build a $100B+ company. That conviction led us to invest in Nexthop AI from Day One,” said Guru Chahal, Partner at Lightspeed Venture Partners. “Nexthop is uniquely positioned to become the next great networking vendor by combining hyperscale
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom